| |
Presentation |
Webcast |
|
November 22, 2023
Investor call with management team
|
|
|
|
Oktober 2, 2023
Presentation with CEO Jenny Sundqvist and CSO Charlotte Admyre at Redeye Autoimmune & Inflammatory Disease Event
|
|
|
|
August 31, 2023
Company presentation with CEO Jenny Sundqvist and CFO Johan Giléus at HC Andersen Capitals Life Science Seminar
|
|
|
|
August 2, 2023
Interview with CEO Jenny Sundqvist explaining the importance of the formulation patent for cobitolimod that was recently granted in Europe
|
|
|
|
June 19, 2023
Investor update with CEO Jenny Sundqvist and Deputy CEO and CFO Johan Giléus
|
|
|
|
June 1, 2023
In focus interview with CEO Jenny Sundqvist at Redeye Growth Day 2023
|
|
|
|
June 1, 2023
Investor call regarding license agreement in Japan
|
|
|
|
May 9, 2023
Business update with management team
|
|
|
|
April 20, 2023
Company presentation with CEO Jenny Sundqvist at Redeye Investor Forum Göteborg
|
|
|
|
March 28, 2023
Presentation with CEO Jenny Sundqvist and CDO Eva Arlander on the results of the PK study with cobitolimod
|
|
|
|
February 23, 2023
Interview with CEO Jenny Sundqvist regarding the year-end report for 2022
|
|
|
|
February 14, 2023
Presentation with CEO Jenny Sundqvist providing complementary information on the phase III program CONCLUDE with cobitolimod
|
|
|
|
February 13, 2023
Get to know interview with CEO Jenny Sundqvist
|
|
|
SVE
ENG
